EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparing The Efficacies Of Repetitive Transcranial Magnetic Stimulation Therapy (rTMS) And Selective Serotonin Reuptake Inhibitors (SSRIs) In The Treatment Of Depression: A Randomized Double-Blind Placebo-Controlled Trial

Abdullahi Yakubu, Muhammad Aliyu, Audu Aveka, Umar Muhammad, Ahmed Isa, Tajudeen Abiola, Surajudeen Abdulkadir, Summayyah Bashar, Bashir Yakasai, Erin Babatunde, Olasubulu Adebowale, Udofia Owoidoho

Nigerian Journal of Psychiatry · 2026 · 24 (2) · 1

DOI: 10.5455/njp.234359 ↗
AbstractBibliografische Angaben

Abstract

Background: Depression remains a global health challenge, with many patients failing to achieve sustained remission using conventional treatments. This randomized, double-blind, placebo-controlled trial compared the efficacy of repetitive transcranial magnetic stimulation (rTMS) and Fluoxetine (an SSRI) in treating major depressive disorder (MDD). Objective: This study compared the efficacy of rTMS to Selective Serotonin Reuptake Inhibitors (SSRIs) in treating depression. Methods: Forty adults with MDD were randomized to receive either rTMS (twice weekly for 6 weeks; n = 20) or Fluoxetine (20 mg/day for 6 months; n= 20). Sham procedures controlled for placebo effects. Depression severity was measured using the Hamilton Depression Rating Scale (HAM-D) at baseline, 6 weeks, 6 months, and 12 months. Data were analyzed via mixed-design ANOVA. Results: Both treatments significantly reduced HAM-D scores over time (p < .001, η² = 0.997). While no main effect of treatment was observed (p =.15, η² = 0.054), rTMS showed superior long-term efficacy. At 6 months, rTMS achieved near-remission (mean HAM-D = 0.20 vs. 1.10 for Fluoxetine; p < .001, 95% CI [−1.12, −0.68]). At 12 months, rTMS maintained a lower symptom burden (mean HAM-D = 7.30 vs. 9.30; p = .017, 95% CI [−3.92, −0.08]) The time × treatment interaction was significant (p = .017, η² = 0.243), indicating rTMS’s sustained benefit. Conclusion: rTMS may offer more durable antidepressant effects than Fluoxetine, particularly beyond 6 months. These findings support rTMS as a first-line intervention for MDD, though larger trials are needed to confirm its long-term advantage.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →